# CNS PHARMACEUTICALS INC (CNSP)

> Institutional ownership reported to the SEC as of Q2 2026, from Form 13F filings. Source: https://holderbook.com/stocks/CNSP/

- Reporting holders: 11
- Reported value: $7.8M
- Shares held by institutions: 1,626,355 of 1,461,449 outstanding
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Stonepine Capital Management, LLC](https://holderbook.com/funds/1440771-stonepine-capital-management-llc/) | $6.6M | 1,387,494 | 1.7% | 3 |
| [Ikarian Capital, LLC](https://holderbook.com/funds/1778253-ikarian-capital-llc/) | $649.3K | 135,830 | 0.1% | 3 |
| [ADAR1 Capital Management, LLC](https://holderbook.com/funds/1940272-adar1-capital-management-llc/) | $334.6K | 70,000 | 0.0% | 1 |
| [BOOTHBAY FUND MANAGEMENT, LLC](https://holderbook.com/funds/1549230-boothbay-fund-management-llc/) | $64.6K | 13,524 | 0.0% | 3 |
| [VANGUARD FIDUCIARY TRUST CO](https://holderbook.com/funds/933478-vanguard-fiduciary-trust-co/) | $48.9K | 10,226 | 0.0% | 1 |
| [VANGUARD CAPITAL MANAGEMENT LLC](https://holderbook.com/funds/2100119-vanguard-capital-management-llc/) | $33.4K | 6,993 | 0.0% | 1 |
| [UBS Group AG](https://holderbook.com/funds/1610520-ubs-group-ag/) | $7.0K | 1,461 | 0.0% | 4 |
| [Tower Research Capital LLC (TRC)](https://holderbook.com/funds/1533421-tower-research-capital-llc-trc/) | $3.8K | 799 | 0.0% | 2 |
| [BARCLAYS PLC](https://holderbook.com/funds/312069-barclays-plc/) | $91 | 19 | 0.0% | 1 |
| [BARRETT & COMPANY, INC.](https://holderbook.com/funds/887602-barrett-company-inc/) | $38 | 8 | 0.0% | 4 |
| [DANSKE BANK A/S](https://holderbook.com/funds/800177-danske-bank-a-s/) | $5 | 1 | 0.0% | 4 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q2 2026 | 11 | $7.8M |
| Q1 2026 | 12 | $348.7K |
| Q4 2025 | 10 | $652.4K |
| Q3 2025 | 8 | $221.5K |
| Q2 2025 | 11 | $421.8K |
| Q1 2025 | 7 | $55.2K |
| Q4 2024 | 15 | $297.3K |
| Q3 2024 | 9 | $75.3K |
| Q2 2024 | 10 | $227.8K |
| Q1 2024 | 18 | $351.1K |
| Q4 2023 | 16 | $425.4K |
| Q3 2023 | 12 | $131.7K |